Pages that link to "Q33813143"
Jump to navigation
Jump to search
The following pages link to NMDA receptor hypofunction model of schizophrenia (Q33813143):
Displaying 50 items.
- Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour? (Q22306157) (← links)
- A default mode of brain function (Q24544311) (← links)
- Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics (Q24561726) (← links)
- General anesthesia, sleep, and coma (Q24611495) (← links)
- Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 (Q24626912) (← links)
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia (Q24646206) (← links)
- Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder (Q24647600) (← links)
- The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia (Q24798030) (← links)
- Prenatal lead exposure, delta-aminolevulinic acid, and schizophrenia (Q24811775) (← links)
- The dysconnection hypothesis (2016) (Q26741916) (← links)
- A Comprehensive Review of the (1)H-MRS Metabolite Spectrum in Autism Spectrum Disorder (Q26751201) (← links)
- DTI and Myelin Plasticity in Bipolar Disorder: Integrating Neuroimaging and Neuropathological Findings (Q26765967) (← links)
- Novel NMDA receptor modulators: an update (Q26849614) (← links)
- NMDA receptor modulators: an updated patent review (2013-2014) (Q26997407) (← links)
- Neuroimaging of frontal-limbic dysfunction in schizophrenia and epilepsy-related psychosis: toward a convergent neurobiology (Q27015812) (← links)
- Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion (Q27325106) (← links)
- Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis (Q27490347) (← links)
- DISC1 at 10: connecting psychiatric genetics and neuroscience (Q28250914) (← links)
- The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice (Q28260403) (← links)
- Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects (Q28276986) (← links)
- N-methyl-D-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder (Q28285432) (← links)
- Glutamate receptor ion channels: structure, regulation, and function (Q28290774) (← links)
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders (Q28302151) (← links)
- The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: a putative link between metabolism and an animal model of psychosis (Q28574077) (← links)
- The antipsychotic potential of muscarinic allosteric modulation (Q28603221) (← links)
- Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease (Q28660933) (← links)
- The p250GAP gene is associated with risk for schizophrenia and schizotypal personality traits (Q28730526) (← links)
- Mismatch Negativity in First-Episode Schizophrenia: A Meta-Analysis (Q30250337) (← links)
- Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. (Q30355619) (← links)
- Investigating Cortical Inhibition in First-Degree Relatives and Probands in Schizophrenia (Q30358965) (← links)
- Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end? (Q30379983) (← links)
- Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. (Q30383064) (← links)
- Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity. (Q30384905) (← links)
- Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection (Q30386608) (← links)
- Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats (Q30391389) (← links)
- Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate (Q30403302) (← links)
- Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia (Q30403790) (← links)
- Animal Models of Psychosis: Current State and Future Directions (Q30410153) (← links)
- Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia (Q30413012) (← links)
- Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead (Q30418734) (← links)
- Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders. (Q30426586) (← links)
- Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment (Q30428213) (← links)
- Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression (Q30437684) (← links)
- How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia (Q30439924) (← links)
- D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors. (Q30453020) (← links)
- Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia (Q30457809) (← links)
- Targeting glutamate synapses in schizophrenia (Q30460392) (← links)
- Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia (Q30465586) (← links)
- Annual Research Review: Transgenic mouse models of childhood‐onset psychiatric disorders (Q30469044) (← links)
- Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus (Q30470074) (← links)